Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for treatment of some malignant and non-malignant hematological diseases. However, post-HSCT patients are severely immunocompromised and susceptible to viral infections, which are a major cause of morbidity and mortality. Although antiviral agents are now available for most types of viral infections, they are not devoid of side effects and their efficacy is limited when there is no concomitant antiviral immune reconstitution. In recent decades, adoptive transfer of viral-specific T cells (VSTs) became an alternative treatment for viral infection after HSCT. However, two major issues are concerned in VST transfer: the risk of GVHD and antiviral efficacy. We report an exhaustive review of the published studies that focus on prophylactic and/or curative therapy by donor VST transfer for post-HSCT common viral infections. A low incidence of GVHD and a good antiviral efficacy was observed after adoptive transfer of VSTs from HSCT donor. Viral-specific T-cell transfer is a promising approach for a broad clinical application. Nevertheless, a randomized controlled study in a large cohort of patients comparing antiviral treatment alone to antiviral treatment combined with VSTs is still needed to demonstrate efficacy and safety.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Feuchtinger T, Richard C, Pfeiffer M, Neuhauser F, Lucke J, Handgretinger R et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update. Klin Padiatr 2005; 217: 339–344.

    CAS  Article  Google Scholar 

  2. Bollard CM, Heslop HE . T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 2016; 127: 3331–3340.

    CAS  Article  Google Scholar 

  3. Roddie C, Peggs KS . Immunotherapy for transplantation-associated viral infections. J Clin Invest 2017; 127: 2513–2522.

    Article  Google Scholar 

  4. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925–935.

    CAS  Article  Google Scholar 

  5. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379–386.

    CAS  Article  Google Scholar 

  6. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64–76.

    Article  Google Scholar 

  7. O'Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E . Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections. Bone Marrow Transplant 2016; 51: 1163–1172.

    CAS  Article  Google Scholar 

  8. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038–1044.

    CAS  Article  Google Scholar 

  9. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916–3922.

    CAS  Article  Google Scholar 

  10. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397–4406.

    CAS  Article  Google Scholar 

  11. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375–1377.

    Article  Google Scholar 

  12. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 707–714.

    CAS  Article  Google Scholar 

  13. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112: 3974–3981.

    CAS  Article  Google Scholar 

  14. Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M . Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008; 40: 63–67.

    CAS  Article  Google Scholar 

  15. Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121: 3745–3758.

    CAS  Article  Google Scholar 

  16. Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant 2015; 21: 1663–1678.

    CAS  Article  Google Scholar 

  17. Bao L, Cowan MJ, Dunham K, Horn B, McGuirk J, Gilman A et al. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections. J Immunother 2012; 35: 293–298.

    CAS  Article  Google Scholar 

  18. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814.

    CAS  PubMed  Google Scholar 

  19. Imashuku S, Goto T, Matsumura T, Naya M, Yamori M, Hojo M et al. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant 1997; 20: 337–340.

    CAS  Article  Google Scholar 

  20. Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F . T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008; 40: 68–70.

    CAS  Article  Google Scholar 

  21. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119: 2644–2656.

    CAS  Article  Google Scholar 

  22. Geyeregger R, Freimuller C, Stemberger J, Artwohl M, Witt V, Lion T et al. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J Immunother 2014; 37: 245–249.

    CAS  Article  Google Scholar 

  23. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013; 21: 2113–2121.

    CAS  Article  Google Scholar 

  24. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160–1166.

    CAS  Article  Google Scholar 

  25. Ma CK, Blyth E, Clancy L, Simms R, Burgess J, Brown R et al. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation. Cytotherapy 2015; 17: 1406–1420.

    CAS  Article  Google Scholar 

  26. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6: 242ra283.

    Article  Google Scholar 

  27. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436–442.

    Article  Google Scholar 

  28. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123–1131.

    CAS  Article  Google Scholar 

  29. Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH et al. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol 2014; 167: 402–410.

    Article  Google Scholar 

  30. Gallot G, Vollant S, Saiagh S, Clemenceau B, Vivien R, Cerato E et al. T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study. J Immunother 2014; 37: 170–179.

    CAS  Article  Google Scholar 

  31. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116: 5045–5049.

    CAS  Article  Google Scholar 

  32. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121: 5113–5123.

    CAS  Article  Google Scholar 

  33. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51: 591–599.

    CAS  Article  Google Scholar 

  34. Uhlin M, Gertow J, Uzunel M, Okas M, Berglund S, Watz E et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012; 55: 1064–1073.

    CAS  Article  Google Scholar 

  35. Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dossinger G, Schiemann M et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia 2017; 31: 2161–2171.

    CAS  Article  Google Scholar 

  36. Leen AM, Heslop HE, Brenner MK . Antiviral T-cell therapy. Immunol Rev 2014; 258: 12–29.

    CAS  Article  Google Scholar 

  37. Wy IpW, Qasim W . Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation. Adv Hematol 2013; 2013: 176418.

    Google Scholar 

  38. Lindemans CA, Leen AM, Boelens JJ . How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116: 5476–5485.

    CAS  Article  Google Scholar 

  39. Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986–1994.

    CAS  Article  Google Scholar 

  40. Di Nardo M, Li Pira G, Amodeo A, Cecchetti C, Giorda E, Ceccarelli S et al. Adoptive immunotherapy with antigen-specific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation. Pediatr Blood Cancer 2014; 61: 376–379.

    Article  Google Scholar 

  41. Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115: 2960–2970.

    CAS  Article  Google Scholar 

  42. Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52: 49–57.

    CAS  Article  Google Scholar 

  43. Aissi-Rothe L, Decot V, Venard V, Jeulin H, Salmon A, Clement L et al. Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy. J Immunother 2010; 33: 414–424.

    CAS  Article  Google Scholar 

  44. Qian C, Wang Y, Cai H, Laroye C, De Carvalho Bittencourt M, Clement L et al. Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-gamma Immunomagnetic Selection. J Immunother 2016; 39: 27–35.

    CAS  Article  Google Scholar 

  45. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360–4367.

    CAS  Article  Google Scholar 

  46. Creidy R, Moshous D, Touzot F, Elie C, Neven B, Gabrion A et al. Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation. J Allergy Clin Immunol 2016; 138: 920–924.e923.

    CAS  Article  Google Scholar 

  47. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31: 39–48.

    CAS  Article  Google Scholar 

  48. Hislop AD, Taylor GS, Sauce D, Rickinson AB . Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587–617.

    CAS  Article  Google Scholar 

  49. Milosevic S, Behrends U, Adhikary D, Mautner J . Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach. J Virol 2006; 80: 10357–10364.

    CAS  Article  Google Scholar 

  50. Qasim W, Gilmour K, Zhan H, Derniame S, McNicol AM, Ip W et al. Interferon-gamma capture T cell therapy for persistent adenoviraemia following allogeneic haematopoietic stem cell transplantation. Br J Haematol 2013; 161: 449–452.

    CAS  Article  Google Scholar 

  51. Qian C, Campidelli A, Wang Y, Cai H, Venard V, Jeulin H et al. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial. J Hematol Oncol 2017; 10: 102.

    Article  Google Scholar 

  52. Pello OM, Innes AJ, Bradshaw A, Finn SA, Uddin S, Bray E et al. BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. Eur J Haematol 2017; 98: 632–634.

    CAS  Article  Google Scholar 

  53. Uhlin M, Okas M, Gertow J, Uzunel M, Brismar TB, Mattsson J . A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010; 59: 473–477.

    Article  Google Scholar 

  54. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 2016; 101 (7): 803–811.

    CAS  Article  Google Scholar 

  55. Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D . T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 2014; 14: 768–774.

    CAS  Article  Google Scholar 

  56. Utzschneider DT, Charmoy M, Chennupati V, Pousse L, Ferreira DP, Calderon-Copete S et al. T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity 2016; 45: 415–427.

    CAS  Article  Google Scholar 

  57. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 2016; 537: 417–421.

    CAS  Article  Google Scholar 

  58. Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol 2016; 1: eaai8593.

    Article  Google Scholar 

  59. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009; 114: 4784–4791.

    CAS  Article  Google Scholar 

  60. Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009; 114: 4792–4803.

    CAS  Article  Google Scholar 

  61. Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY et al. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood 2015; 126: 2781–2789.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Bensoussan.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qian, C., Wang, Y., Reppel, L. et al. Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT. Bone Marrow Transplant 53, 114–122 (2018). https://doi.org/10.1038/bmt.2017.232

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.232

Further reading

Search

Quick links